SCHEMBL10169697

SCHEMBL10169697

CCCN1CC(Oc2ccc(C(=O)c3c(-c4ccccc4Cl)noc3-c3ccccc3)cc2)C1

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.45
MAPT P10636 3/20 0.42
POLB P06746 2/20 0.41
LMNA P02545 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
S1PR1 P21453 5/20 0.41
S1PR3 Q99500 4/20 0.41
GPBAR1 Q8TDU6 3/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
ALDH1A1 P00352 2/20 0.40
NPC1 O15118 1/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10169694 0.94 TP53 (0.43) TP53MAPTLMNANPSR1HTT
SCHEMBL9956546 0.94 ESR1 (0.43) TP53MAPTLMNANPSR1SMN1; SMN2
Hydrochloric Acid SCHEMBL9956229 0.93 ESR1 (0.42) TP53MAPTLMNANPSR1SMN1; SMN2
SCHEMBL10169702 0.92 TP53 (0.41) TP53MAPTPOLBLMNANPSR1
Hydrochloric Acid SCHEMBL9956167 0.91 TP53 (0.41) TP53MAPTPOLBLMNANPSR1
SCHEMBL10169692 0.91 TP53 (0.42) TP53MAPTPOLBLMNANPSR1
Trifluoroacetic Acid SCHEMBL9955991 0.91 TP53 (0.39) TP53MAPTPOLBLMNANPSR1
Trifluoroacetic Acid SCHEMBL9959565 0.88 RORC (0.43) TP53MAPTPOLBLMNANPSR1
SCHEMBL9957139 0.87 ESR1 (0.43) TP53MAPTLMNANPSR1S1PR1
SCHEMBL10169845 0.86 ESR1 (0.44) MAPTLMNAHTTSMN1; SMN2S1PR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9540361-B2 N-substituted azetidine derivatives MERCK SHARP & DOHME B.V. (NL) 2017-01-10 US disclosed
US-9540361-B2 N-substituted azetidine derivatives MERCK SHARP & DOHME B.V. (NL) 2017-01-10 US disclosed
US-20160130262-A1 N-SUBSTITUTED AZETIDINE DERIVATIVES MERCK SHARP & DOHME B.V. (NL) 2016-05-12 US disclosed
US-20160130262-A1 N-SUBSTITUTED AZETIDINE DERIVATIVES MERCK SHARP & DOHME B.V. (NL) 2016-05-12 US disclosed
WO-2012084711-A1 N-SUBSTITUTED AZETIDINE DERIVATIVES MSD OSS B.V. (NL) 2012-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160130262-A1 N-SUBSTITUTED AZETIDINE DERIVATIVES ESR2, ESR1, GPER1 TP53 284/4885MAPT 3866/4885POLB 4552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.